A mapping-based universal Kriging model for order-of-addition experiments in drug combination studies

Qian Xiao and Hongquan Xu

Computational Statistics & Data Analysis, 2021, vol. 157, issue C

Abstract: In modern pharmaceutical studies, treatments may include several drugs added sequentially, and the drugs’ order-of-addition can have significant impacts on their efficacy. In practice, experiments enumerating all possible drug sequences are often not affordable, and appropriate statistical models which can accurately predict all cases using only a small number of experimental trials are required. A novel mapping-based universal Kriging (MUK) model and its simplified variant are proposed for analyzing such order-of-addition experiments with blocking. They can provide accurate predictions and have robust performances under various experimental designs. The MUK model can also incorporate available domain knowledge to enhance its interpretation. The superiority of the proposed methods is illustrated via a real five-drug experiment on lymphoma and two simulation examples.

Keywords: Chemotherapy; Experimental design; Gaussian process modeling; Response surface modeling (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0167947320302462
Full text for ScienceDirect subscribers only.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:csdana:v:157:y:2021:i:c:s0167947320302462

DOI: 10.1016/j.csda.2020.107155

Access Statistics for this article

Computational Statistics & Data Analysis is currently edited by S.P. Azen

More articles in Computational Statistics & Data Analysis from Elsevier
Bibliographic data for series maintained by Catherine Liu ().